查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1743731

紅色生物技術市場－全球產業規模、佔有率、趨勢、競爭、機會和預測，按產品類型、應用、最終用戶、地區和競爭細分，2020-2030 年

Red Biotechnology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type, By Application, By End-User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球紅色生物技術市場規模為4,213.2億美元，預計2030年將達到7,741.5億美元，預測期內複合年成長率為10.67%。市場成長的驅動力包括基因工程的不斷進步、針對危及生命的疾病的新型療法日益成長的需求以及精準醫療的蓬勃發展。紅色生物技術涉及利用活細胞和生物分子製程進行治療和診斷，包括生產疫苗、基因療法、診斷試劑和生物製藥。隨著個人化治療和針對特定疾病的療法需求不斷成長，紅色生物技術產業在已開發市場和新興市場都有望顯著成長。

市場概覽
預測期 2026-2030
2024年市場規模 4213.2億美元
2030年市場規模 7741.5億美元
2025-2030 年複合年成長率 10.67%
成長最快的領域 基因重組藥物
最大的市場 北美洲

關鍵市場促進因素

慢性病和罕見疾病管理對生物製藥的需求不斷成長

主要市場挑戰

開發成本高且監管要求複雜

主要市場趨勢

個人化醫療和基因組學療法的擴展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：紅色生物技術市場展望。

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（診斷試劑、人用疫苗、血液製品、基因重組藥物及其他）
    • 按應用（生物製藥生產、基因治療、基因檢測、藥物基因體學、藥物發現等）
    • 按最終用戶（製藥和生物技術公司、CMO 和 CRO、研究機構等）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：亞太紅色生物技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國 。
    • 印度 。
    • 韓國
    • 日本
    • 澳洲

第7章：歐洲紅色生物技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：北美紅色生物技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美洲紅色生物技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲紅色生物技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 併購
  • 產品開發

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 14 章：全球紅色生物技術市場：SWOT 分析

第 15 章：競爭格局

  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bruker Corporation
  • Merck KGaA
  • Celgene Corporation
  • Amgen Inc.
  • Biogen Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 15044

The Global Red Biotechnology Market was valued at USD 421.32 billion in 2024 and is projected to reach USD 774.15 billion by 2030, growing at a CAGR of 10.67% during the forecast period. Market growth is being driven by increasing advancements in genetic engineering, the growing need for novel therapeutics targeting life-threatening diseases, and the surge in precision medicine development. Red biotechnology involves the use of living cells and biomolecular processes for therapeutic and diagnostic applications, including the production of vaccines, gene therapies, diagnostic reagents, and biopharmaceuticals. As demand for personalized treatments and disease-specific therapies continues to expand, the red biotechnology sector is positioned for significant growth across both developed and emerging markets.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 421.32 Billion
Market Size 2030USD 774.15 Billion
CAGR 2025-203010.67%
Fastest Growing SegmentGene Recombinant Drugs
Largest MarketNorth America

Key Market Drivers

Rising Demand for Biopharmaceuticals in Chronic and Rare Disease Management

The increasing prevalence of chronic and rare diseases is a major factor accelerating the demand for red biotechnology, especially in the development of biopharmaceuticals such as recombinant proteins, monoclonal antibodies, and gene therapies. These innovations are addressing unmet medical needs where traditional treatments fall short. According to the World Health Organization (WHO), chronic illnesses-including cancer, cardiovascular diseases, diabetes, and respiratory disorders-account for approximately 74% of all global deaths. In parallel, rare diseases impact over 300 million individuals worldwide. Red biotechnology plays a vital role in the development of precision therapies for these complex health conditions, driving investment and research in this field globally.

Key Market Challenges

High Development Costs and Complex Regulatory Requirements

A major challenge in the red biotechnology market is the substantial cost and complexity associated with developing advanced therapeutics such as gene therapies and biologics. The R&D process involves extensive clinical trials, strict regulatory compliance, and rigorous quality controls, often resulting in long timelines and high expenses. According to the U.S. Congressional Budget Office (CBO), the cost of developing a single biopharmaceutical product can exceed $2.6 billion, and innovations within red biotechnology frequently surpass this due to their technical intricacies. Regulatory bodies such as the FDA and EMA impose detailed requirements for safety, efficacy, and long-term monitoring, particularly for gene-editing therapies. The variability in regulatory frameworks across different countries adds further challenges to global product launches, impacting speed to market and operational efficiency.

Key Market Trends

Expansion of Personalized Medicine and Genomics-Based Therapies

A transformative trend in the red biotechnology market is the rapid advancement of personalized medicine and genomics-driven therapies. Personalized medicine involves tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. Red biotechnology is central to this trend through the development of targeted therapies, gene-editing tools, and molecular diagnostics. The widespread adoption of next-generation sequencing (NGS) and genomic profiling has enabled deeper understanding of disease mechanisms, supporting the creation of patient-specific treatment plans. The declining cost of genome sequencing-from nearly $100 million in 2001 to under $1,000 in 2024-has accelerated clinical integration of genomics, propelling growth in red biotechnology applications.

Key Market Players

  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bruker Corporation
  • Merck KGaA
  • Celgene Corporation
  • Amgen Inc.
  • Biogen Inc.

Report Scope:

In this report, the Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Red Biotechnology Market, By Product Type:

  • Diagnostic Reagents
  • Human Vaccines
  • Blood Products
  • Gene Recombinant Drugs
  • Others

Red Biotechnology Market, By Application:

  • Biopharmaceutical Production
  • Gene Therapy
  • Genetic Testing
  • Pharmacogenomics
  • Drug Discovery
  • Others

Red Biotechnology Market, By End-User:

  • Pharmaceutical and Biotechnology Companies
  • CMO & CRO
  • Research Institute
  • Others

Red Biotechnology Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Red Biotechnology Market.

Available Customizations:

Global Red Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered.
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Red Biotechnology Market Outlook.

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others)
    • 5.2.2. By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery, and Others)
    • 5.2.3. By End-User (Pharmaceutical and Biotechnology companies, CMO & CRO, Research Institute and Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. Asia-Pacific Red Biotechnology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. Asia-Pacific: Country Analysis
    • 6.3.1. China Red Biotechnology Market Outlook.
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. India Red Biotechnology Market Outlook.
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. South Korea Red Biotechnology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User
    • 6.3.4. Japan Red Biotechnology Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By End-User
    • 6.3.5. Australia Red Biotechnology Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By End-User

7. Europe Red Biotechnology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Red Biotechnology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. Germany Red Biotechnology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Red Biotechnology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Red Biotechnology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Red Biotechnology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. North America Red Biotechnology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Red Biotechnology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. Mexico Red Biotechnology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Canada Red Biotechnology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User

9. South America Red Biotechnology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Red Biotechnology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Red Biotechnology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Red Biotechnology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Red Biotechnology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Red Biotechnology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Red Biotechnology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Red Biotechnology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products/Services

14. Global Red Biotechnology Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Pfizer, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Takeda Pharmaceutical Company Limited
  • 15.3. Gilead Sciences
  • 15.4. Regeneron Pharmaceuticals, Inc.
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Bruker Corporation
  • 15.7. Merck KGaA
  • 15.8. Celgene Corporation
  • 15.9. Amgen Inc.
  • 15.10. Biogen Inc.

16. Strategic Recommendations

17. About Us & Disclaimer